Gdc-0449
Adult Epithelioid Hemangioendothelioma
National Cancer Institute (NCI)Phase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Adult Epithelioid Hemangioendothelioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Benzenesulfonamide, N-methyl-3-(1-methyl-1H-imidazol-4-yl)-4-[[[4-(trifluoromethyl)phenyl]methyl]amino]- Ikena Oncology | Phase 1 | CC |
Osimertinib Ikena Oncology | Phase 1 | CC |
rg4733 National Cancer Institute (NCI) | Phase 1/2 | CC |
bgc515 BridGene Biosciences Inc. | Phase 1 | NR |
Same molecule, other indications
Gdc-0449 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →